nasal and vaginal drug delivery systems
TRANSCRIPT
05/03/2023
1
CONCEPTS AND TECHNIQUES OF NASAL AND VAGINAL DRUG DELIVERY SYSTEMS
SUBMITTED TO:Dr. Y.INDIRA MUZIB M.Pharm.,Ph.D.,
SUBMITTED BY:K.DIVYA SHANTHI,2015MPH40008,PHARMACEUTICS.
05/03/2023 2
CONTENTS: INTRODUCTION FACTORS INFLUENCING NASAL ABSORPTION FORMULATION FACTORS TYPES OF NASAL DRUG DELIVERY SYSTEMS EVALUATION STUDIES MERITS AND DEMERITS APPLICATIONS CONCLUSION REFERENCES
05/03/2023 3
INTRODUCTION:• It is also a type of mucoadhesive drug delivery system• In this, drugs are administered through nasal cavity by different
dosage forms like solutions, emulsions, gels etc.,
• NASAL ENZYMES:• Cytochrome p-450 dependent oxygenase , lactase dehydrogenase,
oxydoreductase, acid hydrolases, esterase's, lactic dehydrogenases, malic enzymes, liposomal proteinases, steroid hydroxylases etc.
• NASAL pH:• Adult nasal secretion pH:5.5-6.5• Infants and children: 5-6.7• It become alkaline in conditions such as acute rhinitis, acute sinusitis
05/03/2023 4
ANATOMY OF NASAL CAVITY Nasal cavity is divided into two
halves by nasal spectrum. It contains 3 regions:
Nasal vestibule Olfactory region Respiratory region Nasal cavity is covered with
mucous membrane which contain goblet cells and secrete mucous
a – nasal vestibule d – middle turbinate
b – palate e – superior turbinate (olfactory mucosa)
c – inferior turbinate f – nasopharynx
05/03/2023 5
NOSE BRAIN PATHWAY Olfactory mucosa is in direct contact with the brain and CSF Medications absorbed across the olfactory mucosa directly
enter the brain This area is termed as nose brain pathway and offers a rapid,
direct route for drug delivery to the brain
05/03/2023 6
MECHANISM OF DRUG ABSORPTION• Drug passes through the mucous membrane of nasal cavity• Two mechanisms involved in the transportation of the drug
those are
Para cellular transport
Aqueous route of transport
Slow and passive
Transcellular transport
Transport through lipoidal membraneActive transport occurs via carrier
mediated transport
05/03/2023 7
1. A rapid onset of action is possible through nasal route, for the
administration of systemically acting products.
2. Deposition of an active compound in the nasal cavity results in
avoidance of its degradation through the ‘‘first-pass’’
metabolism.
3. Avoids parentral administration
4. Rapid absorption, peaking generally within 15–30 minutes
5. Apparent permeability to some peptides
6. Ease of self-administration/good patient compliance
Merits:
05/03/2023 8
7.lower doses and less side effects
8.quicker onset of pharmacological activity .
9.User-friendly, painless, non-invasive, needle-free administration
mode.
10.Useful for both local & systemic drug delivery.
11.For CNS drugs, better site for rapid onset of action
Ex. Inhalation anesthesia, Morphine etc.
12.easier to access than IM or IV sites.
05/03/2023 9
Demerits :1. Environmental conditions, infection, and inter-subject
variability can lead to inconsistent absorption.2. Short time span is available for absorption due to rapid
clearance.3. Local metabolism in the nose and instability of compound
(especially for peptide drugs) occur.4. Removal of the therapeutic agent from the site of absorption
is difficult Once administered5. The histological toxicity of absorption enhancers used in nasal
drug delivery system is not yet clearly established.6. Relatively inconvenient to patients when compared to oral
delivery systems since there is a possibility of nasal irritation.
05/03/2023 10
7.Nasal cavity provides smaller absorption surface area when
compared to GIT.
8.There is a risk of local side effects and irreversible damage of the
cilia on the nasal mucosa, both from the substance and from
constituents added to the dosage form.
9.Certain surfactants used as chemical enhancers may disrupt and
even dissolve membrane in high concentration.
10.There could be a mechanical loss of the dosage form into the
other parts of the respiratory tract like lungs because of the improper
technique of administration.
05/03/2023 11
Factors affecting nasal absorption
The various factors affecting nasal absorption are Effect of particle size Effect of molecular size Effect of solution pH Effect of drug lipophilicity Effect of drug concentration
05/03/2023 12
1.Effect of particle size Access to distal airways is a function of particle size Large particles(>7µ)will be lost in the GI tract Small particles(<3µ)will be lost in exhaled breathe Intermediate particles (3 to 7µ) reaches the actual site
2.Effect of molecular size Higher the molecular size, lower the nasal absorption A good systemic bioavailability can be achieved for
Molecules with a molecular weight of up to 1000 Daltons when no absorption enhancer is used.
05/03/2023 13
3.Effect of solution pH; Nasal absorption is pH dependent Absorption is higher at pH lower than the dissociation constant
(pKa) of the molecule Absorption is lower as the pH increases beyond the dissociation
constant• pH of the nasal formulation is important because:1. To avoid the nasal irritation2. To allow drug to be available in unionized form for absorption3. To prevent the growth of pathogenic bacteria in nasal passage4. To maintain functionality of excipients such as preservatives etc.
05/03/2023 14
4.Effect of drug lipophilicity; Polar(water soluble) drugs tend to remain on the tissues of the
upper airway Non-polar(lipid soluble)drugs are more likely to reach distal
airways Lipid soluble drugs are absorbed more rapidly than water
soluble drugs
5.Effect of drug concentration; Absorption depends on the initial concentration of the drug
Absorption follows first order kinetics
05/03/2023 15
General formulation:• Drug viscosifying agents
preservatives solubilizers
Anti-oxidants
05/03/2023 16
Formulation of nasal drug delivery system
• Drugs commonly used in nasal drug delivery are:• β2-adrenergic agonist: Terbutaline sulphate• Corticosteroids: Budesonide• Anti-cholinergic: Ipratropium bromide• Mast cell stabilizer: sodium chromogylate
05/03/2023 17
Viscosifying agents:• Viscosifying agents increases the viscosity of the solution and
that prolongs the therapeutic activity of preparation.• E.g.: Hydroxy propyl cellulose
• Solubilizers:• Aqueous solubility of drug always a limitation for nasal drug
delivery• E.g.: glycol, alcohol, labra sol, transcutol.• In such cases surfactants or cyclodextrins(hp-β-cyclodextrine)are
used, these serve as a biocompatible solubilizers in combination with lipophilic absorption enhancers
05/03/2023 18
Preservatives: These are used to prevent the growth of micro organisms E.g.: parabens, benzalkonium chloride, phenyl ethyl alcohol, EDTA
etc.
anti-oxidants: These are used to prevent drug oxidation E.g.: sodium meta bisulphite, sodium bisulphite, butylated hydroxy
toluene, tocopherol etc.
05/03/2023 19
Types of nasal drug delivery systems: Nasal drops Nasal sprays Nasal gels Nasal powders
1.nasal drops:Nasal drops are one of the most convenient and simple systems for nasal deliveryThey are instilled into nose by using a dropperAqueous or oily solutions can be used as the drops these may inhibit the movement of cilia in nasal mucosaIf used for longer periods , may reach the lungs and cause lipoid pneumonia
05/03/2023 20
• Nasal drops should be isotonic having neutral pH and viscosity similar to nasal secretions by using methyl cellulose.
• E.g.: Ephedrine nasal drops• Otrivin nasal drops
05/03/2023 21
2.Nasal sprays:• These are aqueous or alcoholic preparations• Applied to the mucous membrane of nose by atomizer• Only fine droplets are required so they may reach the lungs• By using metered pumps and actuators a nasal spray can deliver an
exact 25-200µm.• E.g.: adrenaline and atropine spray
05/03/2023 22
3.Nasal gels:• These are high viscous thickened solutions or suspensions • Nasal gels helps in the reduction of post-nasal drip due to high
viscosity, reduction of taste impact due to reduced swallowing, reduction of anterior ,leakage of formulation, reduction of irritation by using soothing/emollient excipients and target to mucosa for a better absorption
• E.g.; nasal gel with vitamin b-12
05/03/2023 23
4.Nasal powders:• Nasal powders were developed for the drugs which are having
poor stability• Powder formulation of a drug depends on the solubility, particle
size, aerodynamic properties, nasal irritancy of the active drug and excipients
• E.g.: Salbutamol nasal powder
05/03/2023 24
For an effective administration of therapeutic drugs through the nasal mucosa, the following must be taken into consideration: 1. The method and technique of administration.2. The site of drug deposition3. Droplet size4. Spray characteristics5. The rate of clearance through the ciliary cavity 6. The pathological condition of the nose7. The speed of mucus flow8. The presence of infection and atmospheric conditions [e.g.,
relative humidity (RH)] will affect the efficacy of nasal absorption.
05/03/2023 26
Evaluation of nasal formulations: Various approaches used to determine the drug passes through mucosa from the formulation 1.in vitro diffusion studies: Nasal diffusion cell is fabricated in glass.
Water jacketed recipient chamber has total capacity of 60ml and a flanged top of about 3mm,the lid has 3 openings and each for
sampling, thermometer, and a donar tube has internal diameter of 1.13cm
05/03/2023 27
Nasal mucosa of sheep was separated from sub layer bony tissues and stoned into distilled water containing few drops at gentamycin injection
After complete removal of blood mucosal surface is attached to donar chamber tube.
The donar cell should be placed in such a way that it just touches the diffusion medium in recipient chamber at predetermined intervals, sample(0.5ml)was withdrawn and transferred into amber coloured
ampoules and replaced with suitable solution
Samples were estimated for drug content by suitable analytical techniques
05/03/2023 28
In vivo nasal absorption studies: Whole animal or in vivo model:1. Several animal models have been described for studying drug
absorption through the nasal mucosa.
2. The most convenient model is the anesthesized rat model
developed by Hirai et al.
3. For most non-peptide drugs, the results obtained in rats can
accurately reflect the absorption profiles in humans.
4. Some experimental modifications are possible, with a similar
surgical operation, and can be chosen for special purposes
05/03/2023 29
Rat model:
It has the following steps
1. Rat is anesthetised by IP injection of sodium pentobarbital.
2. Then an incision is made in the neck, the trachea is cannulated with a poly ethylene tube another tube is inserted through oesophagus towards the posterior part of the nasal cavity.
3. The passage of the nasopalatine tract is sealed surgically to prevent the drainage of drug solution from the nasal cavity in to the mouth. The drug solution is delivered to the nasal cavity through either nostril or the oesophageal tubing.
4. The blood samples are then collected from the femoral vein and analysed for absorbed drug.
05/03/2023 31
Rabbit model
It has the following steps1. A rabbit weighing 3 kg is anaesthetised by an IM injection of a
combination of ketamine and xylazine.
2. The drug solution is delivered by nasal spray into each nostril while the rabbits head is held in an upright position.
3. The rabbit is permitted to breath normally through nostrils and body temperature maintained at 37°C by a heating pad.
4. The blood samples are collected in the marginal ear vein. Ex: Progesterone and its hydroxyl derivatives.
05/03/2023 32
In-vivo in-situ model1. Following the same surgical operation as in the in vivo model, the
drug remaining in the nasal cavity can be recovered at a predetermined time and analysed in this simple model.
2. This method is useful for evaluating both the absorption and the degradation of peptides.
3. Other than the rat & rabbit model, dogs, monkeys, and sheep are also used for in vivo studies.
4. In such large animals, the formulation can be administered while the animal is under anaesthesia or, in some cases, under conscious conditions and care should be taken for physical loss of the formulation because of drainage.
05/03/2023 33
Ex vivo nasal perfusion model
1. During perfusion studies, a funnel is provided underneath the nose to lead the drug solution, which is flowing out of nasal cavity in the drug reservoir(37°C) and circulated through the nasal cavity of the rat by means of a peristaltic pump.
2. The perfusion solution passes out from the nostril and through the funnel and flows in to the drug reservoir solution again. Drug solutions of 3–20mL are continuously circulated through the nasal cavity of anesthetized rats.
3. The reservoir is stirred constantly and the amount of drug absorbed is determined by measuring the drug concentration remaining in the solution after a period of perfusion.
05/03/2023 34
Applications• Delivery of non-peptide
pharmaceuticals• Delivery of peptide based
pharmaceuticals• Delivery of diagnostic drugs
05/03/2023 35
1)delivery of non-peptide pharmaceuticalsDrugs with extensive pre-systemic metabolism, such as
1) Adrenal corticosteroids
2) Sex hormones: 17ß-estradiol, progesterone and testosterone.
3) Vitamins: vitamin B 4) Cardiovascular drugs: hydralazine, Angiotensin II antagonist, nitro-glycerine, propranolol, and colifilium tosylate.
5) Autonomic nervous system: a. Sympathomimetics : Ephedrine, epinephrine, phenylephrine,Xylometazoline, dopamine and dobutamine. b. Parasympathomimetics : nicotine, metacholine c. Parasympatholytics : scopolamine, atropine, ipatropium
can be rapidly absorbed through the nasal mucosa with a systemic
bioavailability of approximately 100%
05/03/2023 36
2.delivery of peptide-based pharmaceuticals
Peptides & proteins have a generally low oral bioavailability
because of their physico-chemical instability and susceptibility to
hepato-gastrointestinal first-pass elimination
E.g.: Insulin, Calcitonin, Pituitary hormones etc.
Nasal route is proving to be the best route for such
biotechnological products
05/03/2023 37
3.delivery of diagnostic drugs
Diagnostic agents such as
Phenol sulfonphthalein – kidney function
Secretin – pancreatic disorders
Penta gastrin – secretory function of gastric acid
05/03/2023 38
Delivery of vaccines through nasal route
Nasal delivery of vaccines has been reported to not only
produce systemic immune response, but also local immune
response in the nasal lining, providing additional barrier of
protection
Recently, for the diseases like anthrax and influenza are treated
by using the nasal vaccines prepared by using the recombinant
Bacillus anthracis protective antigen and chitosan respectively
05/03/2023 39
Conclusion: An accessible alternative route for drug administration.
Provides future potential for several drugs through the
development of safe and efficacious formulations for simple,
painless and long‐term therapy.
Drugs can be directly target to the brain in order to attain a good
therapeutic effect in CNS with reduced systemic side effects.
Much has been investigated and much more are to be investigated
for the recent advancement of nasal drug delivery system.
05/03/2023
40
VAGINAL DRUG DELIVERY SYSTEMSo IntroductionoAnatomy & Physiology of female reproductive systemo Intravaginal DDSo Factors affecting vaginal absorptiono Ideality of Intravaginal DDSo Classification of Intravaginal DDSoAdvantages & Disadvantages o Intrauterine DDSoAdvantages & Disadvantageso Conclusion o References
05/03/2023 41
Introduction:o Vagina and Uterus are the route for administration of
contraceptives , antifungals and antimicrobials.o These are used for local or systemic absorption.o Because of vast network of blood vessels, vaginal wall is
suitable for dug absorption. The rate and extent of drug absorption may vary depends upon:I. Formulation factorsII. PhysiologyIII. Age of patientIV. Menstrual cycle
05/03/2023 43
Vulva:• Basic 5 parts involved:• Mons pubis• Labia majora• Labia minora• Clitoris• vestibules
05/03/2023 44
Vagina:• Muscular canal is about 3 inches long.• Normal pH of vagina in premenopausal female ranges from 4.5 &
rises upto 7 in postmenopausal female.• Vaginal wall surface is covered with epithelium cells.• Size: In premenopausal female 7.8 cm in length & 2 cm wide, in
postmenopausal female 4.5cm in length&1-1.5 cm in width.
05/03/2023 45
Uterus:• Non pregnant uterus is around 7.5cm long, 5cm wide and 2.5cm
thick.• Endometrium is highly vascular made up of simple columnar
epithelium and highly sensitive to hormonal secretions of ovary.• During complete cycle endometrium goes on thickening with
hormonal impact
05/03/2023 46
Fallopian tubules:• Also called ‘Oviducts’ or ‘Uterine tubes’, around 10 cm long.• The end portion is opened and funnel shaped containing finger
like projection called “Fimbriae”.• Internal surface is of ciliated columnar epithelium cells.
05/03/2023 47
Ovary:• Two ovaries, were present one on either side of the uterus.• These are having shape and size of unshelled almonds.• There are ovarian follicles containing oocytes in various stages of
development.• Matured follicle which releases secondary oocyte is called Graafian
follicle.• Ovaries produces hormones including progesterone and estrogen,
inhibin and relaxin.
05/03/2023 48
Intravaginal Drug Delivery System• Traditionally used system as contraceptive and to treat vaginal
infections.• The formulations given by this route are in solid, liquid and
semisolid system.• It may be intended for local effect or systemic action.• Systemic absorption by dense network of blood vessels is
advantage over oral route.• The first truly controlled drug delivery systems for used in
vagina were developed in 1970, when the first vaginal ring was used for delivery of medroxyprogesterone acetate for contraception.
• Vaginal rings are most common long term drug delivery system currently used.
05/03/2023 49
Factors affecting vaginal drug absorption
• It is important to design formulation as well as device used for administration.
• Factors can be categorized as:
1) Physiological factors:- Factors related to the vaginal physiology include: a. pH of vagina (3.5- 4.9) b. Effect of menstrual cycle on permeability of vaginal epithelium c. Vaginal fluid volume d. Viscosity of vaginal fluid e. Pressure exerted by rectal wall on dosage form affect vaginal
blood flow.
05/03/2023 50
2) Physicochemical factors:-
Factors related to physico-chemical properties of drug such as:
a. Viscosity (semisolids)
b. Concentration and Volume for administration
c. Type of dosage form
d. Molecular size of drug
05/03/2023 51
Ideality of Intravaginal DDS1) Component should melt at vaginal temperature i.e. at 37oC.
2) Device should be nontoxic and nonirritating.
3) Formulation should be non sensitive on vaginal pH.
4) Formulation should have wetting and emulsifying properties.
5) It should be stable on storage.
6) Formulation should have proper viscosity to avoid leakage of
drug from vagina (for semisolid).
7) Formulation should have proper bioadhesive properties to
increase contact time between membrane and formulation.
05/03/2023 52
Classification of Intravaginal DDS• There are three types of intra vaginal drug delivery systems they
are vaginal drug delivery systems
localised systemic solid polymeric carriers
05/03/2023 53
1. Localized : 1) Barrier contraception (Diaphragm, Cervical cap, Sponge)
2) Prevention/Treatment of infection ( Gels, Cream, Ointment)
05/03/2023 54
B. Systemic :A. Suppositories or pessaries.
. B. Bio(muco)adhesive semisolids. These are emulsion bases formulation to deliver antifungal agents such as imidazole. Give controlled delivery for 3 or more hours.
05/03/2023 55
C. Solid polymeric carriers: a. Solid hydrogels: Having swelling property which enables the drug to diffuse out of the
macromolecular network. e.g.; Nu-gel ( Johnson & Johnson)
b. Elastomeric intravaginal rings( IVR):1) Matrix (homogeneous dispersion)2) Reservoir (core)3) Sandwich (shell)Elastomer exert slight tension on vaginal wall, more suitable for hydrophobic drugs.Normally designed to contain steroidal hormones.
05/03/2023 56
1) Matrix type :-• Drug is homogeneously dispersed
through out the polymer matrix.• Drug release from this type follows
First order.2) Reservoir type:-• Drug is located within the centralized
core that is surrounded by drug free silicon sheath acts as rate controlling membrane for drug diffusion.
• It follows Zero order fashion.3) Sandwich type:-• Consists of narrow drug containing
layer positioned between non-medicated impervious central core & non-medicated outer rate controlling band.
• Small and constant release of drug.
05/03/2023 57
Other novel approaches:1) Medicated Vaginal Tampons- A medicated vaginal tampon,
approved as a medical device by the Food and Drug Administration (FDA) .
• This bifunctional tampon contains a polymeric delivery system (strips) that absorb menstrual fluid while gradually releasing lactic acid and citric acid.
• eg. Brilliant pH tampons
05/03/2023 58
2) Vaginal Films- • Vaginal films are polymeric drug delivery systems shaped as thin
sheets, usually ranging from 220 to 240 μ m in thickness. • These systems are often square (approximately 5cm × 5cm),
colorless, and soft, presenting a homogenous surface. • Vaginal films are produced with polymers such as polyacrylates,
polyethylene glycol, polyvinyl alcohol, and cellulose derivatives.• eg.VCF (vaginal contraceptive films)
05/03/2023 59
Advantages:• Minimal systemic side effects.• Irritation to the stomach and small intestine associated with some
drugs can be avoided.• An increase in bioavailability.• First pass metabolism can be avoided.• Contact with digestive fluid is avoided, thereby preventing
enzymatic degradation of some drugs.• Self medication is possible.• Drug delivery can be stopped by removing the dosage form. e.g.
vaginal rings• Rapid drug absorption and quick onset of action can be achieved.• The vaginal bioavailability of smaller drug molecule is good.• The bioavailability of larger drug molecules can be improved by
means of absorption enhancer.
05/03/2023 60
Disadvantages• Patient incompliance.• Only few drugs are administered by this route.• Some of the drugs are sensitive at the vaginal pH.• Local irritation because some drugs variability in drug absorption
related with menstrual cycle, menopause and pregnancy.• Gender specificity.• Influence with sexual intercourse.• Some time leakage of drugs from vagina and wetting of
undergarments.
05/03/2023 61
Animal models:Vaginal mucosa permeability:-1) The fundamentals of vaginal absorption of drug can be
studied on female rabbits.
2) It doesn’t exhibit an estrus cycle so its vaginal tissues shows consistency in the histological, biochemical and physiological properties not ordinarily seen in other mammals.
3) But the rabbits may not be suitable for CR dosage forms due to lack of estrus cycle.
4) Rhesus monkeys are excellent animal model for CR dosage form as they are having estrus cycle of approx 28 days like human female.
05/03/2023 62
In-Vitro & In-Vivo Evaluations
In-vitro studies include:Release:
By membrane diffusion studies,
Microbiological methods and
A vaginal dissolution tester.
The bioadhesive strength: - By measuring tensile strength or shear stress required to separate the formulation from the vaginal mucosa.
- Disintegration or dissolution tests, uniformity of content or weight are some of the official tests for pessaries.
05/03/2023 63
In -vivo studies include:
The bioavailability can be determined by:
(1) monitoring quantities of systemically absorbed materials, e.g., peptides & proteins,
(2) measuring the pharmacological activity &(3) analysis of vaginal lavage. - Gamma scintigraphy is a valuable method assessing the distribution, spreading and retention of vaginal formulations in sheep and human females.
- Colposcopy has also been used for direct in-vivo visualization and analysis.
05/03/2023 64
Intrauterine DDS (IUDs)Types of IUDs for controlled drug delivery:-
1) Non-hormonal IUDs. (Ex. copper-T, copper-7)2) Hormonal IUDs. ( Ex. Progestasert)
1) Non-hormonal IUDs/ copper medicated IUDs.• It consists of polyethylene or polypropylene plastic support of
number-7 or letter-T with certain amount of pure electrolytic copper wire wound around them.
• Copper is cytotoxic and enhance spermicidal & spermato depressive action of IUD.
• The exposed surface area of copper is 380 mm2.
• T-shaped IUD is popular since shape conforms to the uterine cavity which resists displacement & rotation within cavity and expulsion from cavity
• Types- Cu T-200--------200 mm². Cu T-30---------30 mm².
05/03/2023 65
2) Hormonal IUDs.• T-shaped device made of polyethylene frame that
measures 32 mm in both vertical and horizontal direction.
• There is silicone reservoir containing dispersed levonogesterol or progesterone on vertical stem and further enclosed in a sleeve of rate controlling membrane of ethylene-vinyl copolymer.
• It prevents pregnancy up to 5 yrs by steadily releasing small amount of progesterone directly in to uterus.
• It works by thickening the cervical mucous so that sperm have more difficulty to swim through uterus.
• For some women it may also prevent ovulation from occurring.
05/03/2023 66
AdvantagesNon-hormonal:-• Safe.
• Immediately and highly effective.
• Long term (up to 10 yrs) effect- Freedom from having to remember to use contraceptives regularly or at the time of intercourse.
• Cost effective (no on going cost after initial insertion)
• Reversible (rapid return of fertility after removal).
05/03/2023 67
Hormonal :-• After about 5 months nearly all women will experience light
periods only.
• After 12 months about 20% of women will have no periods at all.
• Can be used to treat excessively heavy menstrual bleeding
• Reduces period pain in many women.
• May be suitable for women approaching menopause as it provides effective contraception and can continue to be used as the progesterone component for hormone replacement therapy.
05/03/2023 68
DisadvantagesNon-hormonal:-• Requires visit to trained physician for insertion and removal.• Some risk of expulsion within first year.• for some women, increased menstrual bleeding and cramping.• Lack of protection against STDs, including HIV.Hormonal :-• Irregular bleeding pattern in the early stages (irregular bleeding and
cramping during first few weeks or months after insertion.)• Some women experiences backache for several days or weeks after
insertion.• Nausea, headache.• Weight gain.
05/03/2023 69
Conclusion: Bioadhesive vaginal formulations are likely to emerge as new
vaginal formulations for both local and systemic delivery
. With the increasing number of novel polymers each year, the
challenge remains to design appropriate bioadhesive vaginal
formulations.
Vaginal rings have shown significant promise and are well
accepted within female population.
Several combination vaginal contraceptive rings have been found
to provide excellent contraceptive efficacy with little risk of adverse
effects.
05/03/2023 70
The vaginal route has been traditionally used for the local application of drugs, but is now gaining importance as a possible site for systemic delivery.
For the prevention of STD’s AIDS and conception, the use of vaginal products might provide a better path.
Novel developments such as bioadhesive systems and liposomes overcome some of the major limitations of conventional vaginal products.
05/03/2023 71
References:o . Encyclopedia of pharmaceutical technology. 3rd Edition . Vol 1.
Page :1201 by JAMES SWARBRICK.o Chien Y. W. (2007), Novel Drug Delivery Systems, Revised and
Expanded, Marcel Dekker, Inc., New York, Second Indian Reprint , Vol.-50, p. 529-629.
o Bramhmankar D. M. & Jaiswal S. B. (2009), Biopharmaceutics and Pharmacokinetics A Treatise, 2nd edition, Vallabh Prakashan, p. 502-508.
o Chatterjee Arkendu & Kumar Lalit (2009), On overview of Intra-vaginal Drug delivery system, Journal of Pharmacy research, 2 (4) 698-700.